Compositions for gene therapy of rheumatoid arthritis...

Details Compositions for gene therapy of rheumatoid arthritis... Compositions for gene therapy of rheumatoid arthritis...

2007-02-13

2007-02-13

Woitach, Joseph (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093200, C424S093100, C514S04400A, C435S320100

Reexamination Certificate

active

10220824

ABSTRACT:
The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as angiostatin or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.

REFERENCES:
patent: 5770580 (1998-06-01), Ledley et al.
patent: 5792845 (1998-08-01), O'Reilly
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5858355 (1999-01-01), Glorioso et al.
patent: 5861372 (1999-01-01), Folkman et al.
patent: 6140111 (2000-10-01), Riviere et al.
patent: 6156304 (2000-12-01), Glorioso et al.
patent: 6190907 (2001-02-01), Kim et al.
patent: 6201104 (2001-03-01), MacDonald et al.
patent: 2002/0115202 (2002-08-01), Hallenbeck et al.
patent: 1 008 648 (2000-06-01), None
patent: 1 191 036 (2002-03-01), None
patent: 1 197 550 (2002-04-01), None
patent: 9-512173 (1997-12-01), None
patent: 2001-254697 (2001-09-01), None
patent: 2001-256030 (2001-09-01), None
patent: WO 94/07524 (1994-04-01), None
patent: WO 97/15666 (1997-05-01), None
patent: WO 98/12338 (1998-03-01), None
patent: WO 98/51791 (1998-11-01), None
patent: WO 99/65940 (1999-12-01), None
patent: WO 00/00629 (2000-01-01), None
patent: WO 00/40737 (2000-07-01), None
patent: WO 01/73025 (2001-10-01), None
patent: WO 02/45737 (2002-06-01), None
Dixelius, et al. (2000) Blood, 95(11): 3403-11.
Pfeifer, et al. (2001) Fundamental Virology, 4th Ed., Lippincott, Williams, and Wilkins, New York, NY., p. 354.
Robbins, et al. (2003) Gene Therapy, 10: 902-11.
Griscelli, et al. (1998) Proc. Natl. Acad. Sci., USA., 95: 6367-72.
Evans, et al. (1996) Hum. Gene Ther., 7: 1261-80.
□□Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Verma, et al. (1997) Nature, 389: 239-42.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
Yang, et al. (2002) Arthritis Res., 4(3): 215-19.
Kim, et al. (2002) Arthritis & Rheumatism, 46(3): 793-801.
Moore, et al. (2002) Mol. Biol. Cell., 13(12): 4388-400.
Pawliuk, et al. (2002) Molec. Therap., 5(4): 345-51.
Yin, et al. (2002) Molec. Therap., 5(5): 547-54.
Apparailly, et al. (2001) Arthritis & Rheumatism, 44: 1444-54.
Shi, et al. (2002) Cancer Gene Therap., 9: 126-32).
Sieminownow, et al. (2005) Transplantation Proceedings, 37: 201-04.
Bakker, A.C., et al., “Prevention of Murine Collagen-induced Arthritis in the Knee and Ipsilateral Paw by Local Expression of Human Interleukin-1 Receptor Antagonist Protein in the Knee,”Arth.&Rheum. 40:893-900, Lippincott, Williams & Wilkins (1997).
Byun, J., et al., “Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy,”Gene Ther. 3:780-788, Stockton Press (1996).
Griscelli, F., et al., “Angiostatin gene trasfer: Inhibition of tumor growthin vivoby blockage of endothelial cell proliferation associated with a mitosis arrest,”Proc. Natl. Acad. Sci. USA95:6367-6372, National Academy of Sciences (1998).
Hahn, W., et al., “Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis,”Gene Ther. 11:739-745, Nature Publishing Company (May 2004).
Hong, Y., et al., “Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome,”J. Gene Med. 5:18-29, Wiley Interscience (Jan. 2003, published online Dec. 2002).
Kim, S.H., et al., “Construction of Retroviral Vectors with Improved Safety, Gene Expression, and Versatility,”J. Virol. 72:994-1004, American Society for Microbiology (1998).
Kim, J.-M., et al., “Angiostatin Gene Transfer as an Effective Treatment Strategy in Murine Collagen-Induced Arthritis,”Arth.&Rheum. 46:793-801, American College of Rheumatology (Mar. 2002).
Koch, A.E., “Angiogenesis: Implications for Rheumatoid Arthritis,”Arth.&Rheum. 41:951-962, American College of Rheumatology (1998).
Lee, J.-T., et al., “Engineering the splice acceptor for improved gene expression and viral titer in an MLV-based retroviral vector,”Gene Ther. 11:94-99, Nature Publishing Company (Jan. 2004).
Noguiez-Hellin, P., et al., “Plasmoviruses: Nonviral/viral vectors for gene therapy,”Proc. Natl. Acad. Sci. USA93:4175-4180, National Academy of Sciences (1996).
Nouvel, et al., “The spread if a replication-competent MuLV retroviral vector can be efficiently blocked by deletion variants,”Virol. 204:180-189, Academic Press, Inc. (1994).
O'Reilly, M.S., et al., “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,”Cell79:315-328, Cell Press (1994).
O'Reilly, M.S., et al., “Angiostatin induces and sustains dormancy of human primary tumors in mice,”Nat. Med. 2:689-692, Nature Publishing Company (1996).
Otani, K., et al., “Suppression of Antigen-Induced Arthritis in Rabbits by Ex Vivo Gene Therapy,”J. Immunol. 156:3558-3562, The American Association of Immunologists (1996).
Yu, S.S., et al., “High efficiency retroviral vectors that contain no viral coding sequences,”Gene Ther. 7:797-804, Macmillan Publishers Ltd. (May 2000).
Chen, Q.-R., et al., “Liposomes Complexed to Plasmids Encoding Angiostatin and Endostatin Inhibit Breast Cancer in Nude Mice,”Cancer Res. 59:3308-3312, The American Association for Cancer Research (1999).
Database Biosis, Accession No. PREV199799566462, Abstract of Wooley, P.H., et al., “A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice,”J. Rheumatol. 24:890-898, The Journal of Rheumatology Publishing Company Limited (1997).
Davidoff, A.M., et al., “Retroviral Vector-Producer Cell Mediated Angiogenesis Inhibition Restricts Neuroblastoma Growth In Vivo,”Med. Pedriatr. Oncol. 35:638-640, Wiley-Liss, Inc. (Dec. 2000).
Joki, T., et al., “Continuous Endostatin Release Using Alginate Polysine Polymer Encapsulated Producer Cells,”Proc. Am. Assoc. Cancer Res. 41:524, Abstract No. 3342, American Association of Cancer Research (Mar. 2000).
Kim, J.-M., et al., “Angiostatin Gene Transfer as an Effective Treatment Strategy in Murine Collagen-Induced Arthritis,”Arthritis Rheumatism46:793-801, John Wiley & Sons, Inc. (Mar. 2002).
Oliver, S.J., et al., “Suppression of Collagen-Induced Arthritis Using an Angiogenesis Inhibitor, AGM-1470, and a Microtubule Stabilizer, Taxol,”Cell Immunol. 157:291-299, Academic Press, Inc. (1994).
Tanaka, T., et al., “Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth,”Nature Med. 3:437-442, Nature Publishing Group (1997).
Tanaka, T., et al., “Retroviral and adenoviral mediated transduction of angiostatin cDNA inhibits angiogenesis and tumor growth,”Proc. Am. Assoc. Cancer Res. 38:264, Abstract No. 1774, American Association of Cancer Research (1997).
Tanaka, T., et al., Inhibition of angiogenesis and tumor growth following retroviral-mediated transduction of a modified platelet factor 4 cDNA,Proc. Am. Assoc. Cancer Res. 37:54, Abstract No. 377, American Association of Cancer Res

Affiliated with

Also associated with

Rating

Compositions for gene therapy of rheumatoid arthritis... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for gene therapy of rheumatoid arthritis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for gene therapy of rheumatoid arthritis... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3863754